New Data Presented at the Society for Nuclear Medicine Annual Meeting Supports Efficacy Profile of Imaging Agent [18F]Flutemetamol for Detection of Amyloid Plaque Linked to Alzheimer’s Disease
14:30 EDT 12 Jun 2012 | Businesswire
This article has expired, however you can still
download the PDF.
Preview:
Data presented at the Society for Nuclear Medicine (SNM) Annual Meeting
shows that uptake of the investigational imaging agent [18F]flutemetamol
correlates with a beta amyloid in vivo1 biopsy
and can be quantified using a PET-on...
Other Sources for this Article
GE Healthcare
Aleisia Gibson, 609-514-6046 (office)
201-289-3832
(mobile)
Aleisia.gibson@ge.com
More From BioPortfolio on "New Data Presented at the Society for Nuclear Medicine Annual Meeting Supports Efficacy Profile of Imaging Agent [18F]Flutemetamol for Detection of Amyloid Plaque Linked to Alzheimer’s Disease"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
